Biotech-focused hedge fund Baker Bros. Advisors LP reduced its direct position by $317.8M (-41.5% of directly held shares) at $102.50, a price 32.1% below the 90-day high. This is the fund's first-ever sale of CELC shares, following no prior buys or sells on the ticker, despite 18 analysts maintaining a Strong Buy consensus. Bull: A clean exit by a disciplined fund could remove an overhang if no further sales follow. Bear: The exit represents a major supply shock; watch for a secondary offering or buyback announcement to absorb the shares.

Where it could go — Our 5-6 conviction tier sells have a 50% rate of beating the SPY at 30 days; watch for buyback announcements or new institutional buyers to stabilize the stock.

Director Dalvey David executed a Code-S open-market sale of 25,000 shares at $140.68 on 2026-05-04, reducing holdings from 90,000 to 65,000 shares (−27.8% delta), representing $3.5M in proceeds. This is the insider's first Form 4 filing on record with zero prior Code-P buys or Code-S sales, eliminating any historical pattern anchor for this director. The sale occurred 10 days before earnings (2026-05-14) with consensus EPS of −$1.07, while 18 analysts maintain STRONG BUY consensus (16 buy / 2 hold); if the earnings miss materializes, the stock would need to hold above the $97.49 90d low to avoid invalidating the analyst thesis.

Where it could go — Transaction price $140.68 sits 44.3% above the 90d low ($97.49) and 6.8% below the 90d high ($151.02); bear case triggers if stock breaks below $97.49 post-earnings; bull case requires stock to hold above $130 and earnings to beat consensus −$1.07 EPS to justify the 16-analyst buy rating.